Skip to main content
Fig. 3 | Experimental Hematology & Oncology

Fig. 3

From: Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma

Fig. 3

Clinical impact of surface TREM2 on M-MDSCs on DLBCL patients. A Progression-free survival and B overall survival in DLBCL patients with low, medium, or high normalized levels of surface TREM2 on M-MDSCs. Normalized MFI changes of surface TREM2 on M-MDSCs being grouped into < 2%, 2–44%, and > 44%; cut-off values for normalized MFI changes of surface TREM2 determined by ROC analysis and AUC. HR, hazard ratio; M-MDSCs, monocytic myeloid-derived suppressor cells; MFI, mean fluorescence intensity; mOS, median overall survival; mPFS, median progression-free survival; n, number; NR, non-reach; TREM2, triggering receptors expressed on myeloid cells 2

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us